New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving treatment ...
GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS®and ADVAIR® DISKUS® in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, ...
GlaxoSmithKline has received approval in Japan for its key respiratory product Seretide/Advair Diskus and its anti-thrombotic Arixtra, a move which the company says should make a significant ...
Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates, clinicians may ...
Results of the European INSPIRE (Investigating New Standards for Prophylaxis in Reduction of Exacerbations) study, published in the American Journal of Respiratory and Critical Care Medicine (2008: ...
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Mar 14, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from ...
This study has demonstrated that doubling the dose of Seretide™ administered via the Diskus™ inhaler over a short period is safe and well tolerated. Whilst this is not a recommended treatment approach ...
New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving treatment ...
GlaxoSmithKline plc and Theravance, Inc. today announced positive results from three phase III studies. Two studies comparing the efficacy and safety of the combination anticholinergic / long-acting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback